The genetic or pharmacological inhibition of Vps34 kinase activity using SB02024 or SAR405 (Vps34i) decreased tumour growth and improved mouse survival in multiple tumour models (melanoma and CRC) by inducing the infiltration of CD8+, CD4+ T effector cells and NK cells (130). This evidence concerns the gene CD8A and neoplasm.